Zeiss
Manufactures high-precision optical instruments and devices
Content Strategy Intern
About the job
- A Bachelor’s degree with at least four completed semesters in online marketing, marketing communications, media or communications studies, information management, corporate communications, or a comparable degree program.
- A structured, proactive, reliable, and independent working approach.
- Interest in teamwork, communication, and organization.
- Strong interest in content marketing, social media, innovation, digitalization, and sustainability.
- Strong numerical affinity, very good analytical thinking, and a high interest in data analytics.
- Very good Microsoft Office knowledge, especially PowerPoint, or experience with agile collaboration tools such as Microsoft Teams and Miro, as well as social-listening and web-analytics tools.
- Very good written and spoken German and English skills, plus experience in an international environment.
- Contribute to corporate content projects and campaigns.
- Support data analyses and insight generation to optimize content-campaign performance and derive recommendations for action.
- Contribute to developing and improving end-to-end content collaboration, including content collaboration tools, processes, data, and analytics.
- Help create data-and-analytics reports, analyses, and presentations and visualize them.
- Support the interdisciplinary project team in agile working, including organizing, preparing, and documenting meetings and workshops.
- Support editorial topic planning and implementation.
- Independently prepare presentations, conduct research on content trends, formats, and topics relevant to ZEISS, document findings, and present them.
About the company
ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
- ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
- EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.
What critics are saying
- ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
- Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
- ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.
What makes Zeiss unique
- ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
- ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
- ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.
ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.
ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.